• Explore /
  • Poster
  • / PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K-mutant metastatic melanoma (MM) who received dabrafenib + trametinib (D+T) in the randomized phase 3 COMBI-v study.

PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K-mutant metastatic melanoma (MM) who received dabrafenib + trametinib (D+T) in the randomized phase 3 COMBI-v study.

Abstract Poster

Authors

null

Dirk Schadendorf

University Hospital of Essen, Essen, Germany

Dirk Schadendorf , Georgina V. Long , Jean Jacques Grob , Paul D. Nathan , Antoni Ribas , Michael A. Davies , Keith T. Flaherty , Matthew Squires , Savina Jaeger , William Powell , Puay Tan , Caroline Robert

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT01597908

Citation

J Clin Oncol 35, 2017 (suppl; abstr 9527)

DOI

10.1200/JCO.2017.35.15_suppl.9527

Abstract #

9527

Poster Bd #

135

Abstract Disclosures

Similar Posters

First Author: Dirk Schadendorf

First Author: Reinhard Dummer

First Author: Nikhil I. Khushalani

First Author: Caroline Robert